Introduction {#Sec1}
============

Rectal cancer accounts for approximately 28 % of all colorectal malignancies \[[@CR1], [@CR2]\]. Albeit that neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME) surgery is now recommended for clinical stage II/III rectal cancer, it remains controversial whether this is applicable to patients with clinical stage T3N0. Due to the great CRT expenses and increased toxicities and other causes, it is a common phenomenon in China that parts of patients with clinical stage T3N0 rectal cancer fail to receive neoadjuvant CRT at the initial time. Additionally, some patients with clinical stage T1--2N0 may be upstaged with pathological T3N0M0 after radical resection. Thus, it is the question whether postoperative adjuvant treatment should be delivered to those patients who avoid preoperative chemoradiotherapy and are staged with pathological T3N0 after complete radical resection. Considering the inaccuracy of imaging, only pathological diagnosed T3N0 after resection were entered into this study. As postoperative adjuvant chemotherapy is recommended to rectal cancer staged with T4N0M0 (stage II) according to ESMO guideline, these sort of patients are excluded for analysis. Since the current evidence of significant advantage of neoadjuvant over adjuvant chemoradiotherapy in the whole stage II/III group of patients \[[@CR3]\], it is not ethical to conduct a randomized controlled trial to investigate whether adjuvant treatment could be safely omitted in this special group of patients at the present time. Therefore, in the absence of definite knowledge of the benefit from adjuvant treatment for T3N0 disease in the TME era, it is of particular importance to identify high-risk patients to obtain survival gains from adjuvant treatment and low-risk patients to free from adjuvant treatment toxicities and expenses.

Evidence indicates that cancer-associated inflammation plays a key role in the development and survival of a broad range of cancers \[[@CR4]\]. Peripheral blood monocyte is the key immune cell in the inflammatory response, and has been independently associated with the prognosis of various malignancies, such as diffuse large B cell lymphoma \[[@CR5]\], hepatocellular carcinoma \[[@CR6]\], cervical cancer \[[@CR7]\], metastatic melanoma \[[@CR8]\], and lung adenocarcinoma \[[@CR9]\]. However, it is still unknown if monocyte can predict the survival of patients with rectal cancer. This study assessed the prognostic impact of preoperative monocyte count on the survival of pathological T3N0M0 patients.

Material and methods {#Sec2}
====================

Patients {#Sec3}
--------

This retrospective study was approved by the Institutional Review Board at Sun Yat-sen University Cancer Center, and individual informed consent was waived given the anonymous analysis of routine data. A total of 270 rectal cancer patients who underwent TME between June 2004 and November 2011 were included. All patients were pathologically staged T3N0M0 after surgery. Moreover, all patients received complete preoperative evaluation, including endorectal ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), chest radiography, blood count, and liver function test. Baseline monocytes count was established from peripheral blood samples within 1 week before the initiation of any treatment modality. To exclude the influence of various comorbidities or other disease states, all included patients had no self-reported acute infections or rectal disorders, indicating that the cell counts could represent the baseline value.

Treatment {#Sec4}
---------

Surgical resection was defined as radical when there was no evidence of distant metastases and tumor clearance was both macroscopically and histologically complete. All the operations were carried out according to the TME-principles by colorectal surgeons, and the methods included low anterior resection (LAR) and abdominoperineal resection (AR).

Follow-up {#Sec5}
---------

Patients were examined every 3 months during the first 2 years, with follow-up examinations every 6 months thereafter. Evaluations included complete blood count, liver function test, CEA, CA19-9, physical examination, and digital rectal examination. Chest radiography, CT scanning of the abdomen and pelvis, and colonoscopy were conducted every 6 months after surgery.

Statistical analysis {#Sec6}
--------------------

The optimal cut-off value of monocyte count was determined using receiver operating characteristic (ROC) curve analysis. At each value, sensitivity and specificity were plotted, thus generating an ROC curve. The score closest to the point with both maximum sensitivity and specificity was selected as the cut-off value. Covariates balance between low- and high-monocyte groups were examined by *t* test (continuous variable), *χ* ^2^ test, or Fisher's exact test (categorical variable) as appropriate.

The main endpoints were overall survival (OS) and disease-free survival (DFS), defined as the time of surgery to the date of death from all causes, and to the date of either locoregional recurrence, distant metastasis, respectively. OS and DFS rates were estimated with Kaplan--Meier method and log-rank test. Multivariate analysis was performed by Cox proportional hazards regression with backward LR method. Two-sided *P* \< 0.05 was considered to be statistically significant. All statistical analyses were performed by SPSS software, version20.

Results {#Sec7}
=======

Patients {#Sec8}
--------

The median follow-up of all patients was 53 months (range, 3--106 months). There were 19 (7.0 %) cases of locoregional relapse, 37 (13.7 %) cases of distant metastasis, and 32 (11.9 %) cases of death, respectively. The 3- and 5-year OS was 94.1 and 89.8 %, respectively, and the 3- and 5-year DFS was 90.1 and 84.5 %, respectively.

According to the ROC curve analysis (Fig. [1](#Fig1){ref-type="fig"}), patients were stratified into low- and high-monocyte group by the optimal cut-off value of 595/mm^3^. The clinicopathological characteristics were summarized in Table [1](#Tab1){ref-type="table"}. Obviously, high-monocyte count (≥595/mm^3^) was significantly associated with male (*P* \< 0.001), elevated CEA level (≥5 μg/L) (*P* = 0.016), and high tumor grade (*P* = 0.031). However, patients with low-monocyte count (\<595/mm^3^) were quite similar to those with high-monocyte count in age, tumor location, operation, and adjuvant chemotherapy.Fig. 1Receiver operating characteristic analysis Table 1Comparison of clinicopathological characteristics between all the pT3N0M0 patients with low- and high-monocyte countsCharacteristics\<595/mm^3^≥595/mm^3^*P*No.%No.%Sex\<0.001 Male10255.16677.6 Female8344.91922.4Age (years)0.808 \<619048.64047.1 ≥619551.44552.9CEA level0.016 Normal11863.84148.2 Elevated6736.24451.8Tumor location0.772 ≤5 cm5127.62225.9 \>5 cm13472.46374.1Operation0.158 AR15181.66374.1 APR3418.42225.9Tumor grade0.031 I94.91011.8 II16488.66576.5 III126.51011.8Adjuvant therapy0.361 No5831.42225.9 Yes12768.66374.1*AR* anterior resection, *APR* abdominoperineal resection

OS and DFS according to monocyte count {#Sec9}
--------------------------------------

The 3- and 5-year OS rate was 96.1 and 94.2 % for patients with low-monocyte count, and 87.7 and 79.2 % for those with high-monocyte count. Correspondingly, the 3- and 5-year DFS rate was 91.6 and 86 % for patients with low-monocyte count, and 75.8 and 67.8 % for those with high-monocyte count, respectively. Apparently, patients with low-monocyte count had significantly superior OS and DFS over those with high-monocyte count (*P* = 0.006 and *P* \< 0.001, respectively, Fig. [2a, b](#Fig2){ref-type="fig"}).Fig. 2Overall survival (**a**) and disease-free survival (**b**) of patients with low- and high-monocyte counts

Adjusting for the known covariates including sex, age, CEA level, tumor location, operation, tumor grade, and adjuvant chemotherapy, patients with high-monocyte count still showed significantly higher risk of death (HR = 2.55, 95 % CI 1.27--5.10; *P* = 0.008) and disease (HR = 2.63, 95 % CI 1.48--4.69; *P* = 0.001) than those with low-monocyte count (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate analysis of potential prognostic factorsOverall survivalDisease-free survivalUnadjusted PAdjusted HR (95 % CI)Adjusted *P*Unadjusted *P*Adjusted HR (95 % CI)Adjusted *P*Monocyte (\<595/mm^3^ vs ≥595/mm^3^)0.0062.55 (1.27--5.10)0.008\<0.0012.63 (1.48--4.69)0.001Sex (male vs female)0.1150.63 (0.28--1.41)0.2580.0460.59 (0.30--1.14)0.117Age (\<61 vs ≥61 years)0.5301.23 (0.60--2.52)0.5810.0691.65 (0.91--3.00)0.096CEA level (normal vs elevated)0.7041.01 (0.49--2.09)0.9770.0111.72 (0.96--3.08)0.070Tumor location (≤5 vs \>5 cm)0.9990.81 (0.30--2.14)0.6640.2910.67 (0.37--1.24)0.202Operation (AR vs APR)0.9590.89 (0.38--2.08)0.7960.8850.52 (0.22--1.21)0.128Tumor grade (I/II/III)0.9360.84 (0.39--1.81)0.6620.9770.98 (0.50--1.93)0.945Adjuvant therapy (no vs yes)0.5740.76 (0.36--1.62)0.4820.8850.88 (0.46--1.71)0.713*AR* anterior resection, *APR* abdominoperineal resection, *HR* hazard ratio, *CI* confidence interval

Subgroup analysis {#Sec10}
-----------------

Given the above positive association of monocyte count with sex, CEA level, and tumor grade, there might be possible interactions between them. To clarify the influence, thus, we did the subgroup analysis (Table [3](#Tab3){ref-type="table"}). In the male patients, monocyte count was independently associated with both OS (HR = 2.85, 95 % CI 1.24--6.51; *P* = 0.013) and DFS (HR = 2.73, 95 % CI 1.39--5.37; *P* = 0.004). However, the prognostic impact of monocyte count was observed for DFS (HR = 4.69, 95 % CI 1.44--15.34; *P* = 0.011), but not for OS (HR = 1.55, 95 % CI 0.29--8.24; *P* = 0.606) among the females. Similarly, the associations of monocyte count with DFS were observed in all the patients regardless of the CEA level; nevertheless, the significant relations of monocyte count with OS were only obtained in the strata of patients with normal CEA level. Additionally, monocyte count was significantly correlated with OS and DFS among patients with tumor grade II, instead of grades I and III. And for patients with adjuvant therapy, monocyte count was the prognostic factor for OS and DFS, whereas for those with operation alone, monocyte count was just independently predictive of DFS.Table 3Subgroup analysis of the association between monocyte count and overall survival and disease-free survivalSubgroupOverall survivalDisease-free survivalNo. at risk/No. of eventsHR95 % CI*P*\*No. at risk/No. of eventsHR95 % CI*P*\*Low- MOHigh-MOLow-MOHigh-MOSex Male102/966/152.851.24--6.510.013102/1566/212.731.39--5.370.004 Female83/619/21.550.29--8.240.60683/719/54.691.44--15.340.011CEA level Normal118/841/93.381.31--8.780.012118/1041/103.961.60--9.780.003 Elevated67/744/81.490.54--4.130.44167/1244/162.261.07--4.800.033Tumor grade I9/210/1--0.9609/310/11.400.05--40.790.844 II164/1265/143.051.41--6.590.005164/1865/222.911.54--5.500.001 III12/110/2--0.87412/110/34.630.24--88.400.309Adjuvant therapy No58/622/41.350.35--5.140.66258/722/73.201.05--9.750.041 Yes127/963/133.261.39--7.640.007127/1563/192.971.51--5.860.002*HR* hazard ratio, *CI* confidence interval, *MO* monocyte count\*Adjusted for sex, age (\<61 vs ≥61 years), CEA level (\<5 vs ≥5 μg/L), tumor location (≤5 vs \>5 cm), operation, tumor grade, and adjuvant chemotherapy except the factor defined as the stratum

Discussion {#Sec11}
==========

To our knowledge, this is the first large-scale study to evaluate the prognostic significance of the absolute monocyte count in pathological T3N0M0 rectal cancer patients treated with TME resection and without undergoing preoperative chemoradiotherapy. We demonstrated that high-monocyte count independently predicted worse survival of patients. This finding was highly consistent with those in hepatocellular carcinoma \[[@CR6]\], cervical cancer \[[@CR7]\], metastatic melanoma \[[@CR8]\], and lung adenocarcinoma \[[@CR9]\].

Unfortunately, the biological reasons behind this correlation remain speculative but previously published experimental studies support the observation. Firstly, it may relate to the insidious progression of cancer disease involving activation of innate immunity \[[@CR10]\]. Monocytes play a key role in innate immunity, constitute nearly 5 % of the circulating white blood cell pool, and exhibit a short half-life in the circulation of a few hours \[[@CR11]\]. The presence of immunocompetent cells within tumors is assumed to reflect the immunological antitumor response. Secondly, the causal link between inflammation and cancer is now well established \[[@CR12], [@CR13]\]. Monocytes, known as the key component of inflammation system, might directly stimulate cancer cell growth by producing various proinflammatory cytokines, such as interleukin-1, interleukin-6, and tumor necrosis factor. In addition, monocytes can be actively attracted to the tumor site and differentiate into tumor-associated macrophages (TAMs) via the cytokines and chemokines produced by tumor cells, such as monocyte chemoattractant protein-1 and vascular endothelial growth factor \[[@CR14], [@CR15]\]. Thus, the circulating level of monocytes may reflect formation or presence of TAMs. Many macrophage-released soluble factors directly stimulate the growth of tumor cells and promote tumor cell migration and metastasis \[[@CR12], [@CR16], [@CR17]\]. Macrophages can produce enzymes and inhibitors that regulate the digestion of the extracellular matrix, hence favoring tumor invasion and migration \[[@CR18], [@CR19]\] and can also contribute to tumor progression by secretion of factors that enhance neoangiogenesis \[[@CR20]\]. Furthermore, TAMs can educate and control invading leukocytes to promote angiogenesis, viability, motility, and invasion \[[@CR21]\]. Additionally, the immunosuppressive activity of TAMs is performed indirectly by the secretion of chemokines that attract T cell subsets lacking cytotoxic function \[[@CR12], [@CR22]\]. It has been reported that the density of TAMs in many tumors correlates with increased angiogenesis, tumor invasion, and poor prognosis \[[@CR23]--[@CR25]\]. And numerous clinical studies support the protumorigenic role of TAMs in human cancers, showing significant correlation between elevated macrophage content and poor clinical outcome \[[@CR23], [@CR25], [@CR26]\].

In the present study, high-monocyte count was positively associated with male, CEA level, and high tumor grade (Table [1](#Tab1){ref-type="table"}), which suggested the potential interactions between them. As shown in the subgroup analysis, all of these covariates together with adjuvant therapy significantly affected the association of monocyte count with OS, but not DFS. One of the most important causes may be the small sample size of included patients and a few deaths. Actually, only CEA level was found to be strongly interacted with monocyte count for OS (*P* = 0.002). Since high CEA level is known to be an adverse prognosis in rectal cancer, thus the prognostic impact of monocyte count among patients with high CEA level, if existed, was likely to be covered by the effect of CEA level.

It is one of the limitations that this was a retrospective study with small sample size, which possibly caused skewed results; however, the included patients were restricted to those diagnosed with pathological T3N0M0, which lowered the uncertainty of staging by images. Moreover, the treatment heterogeneity, especially the influence of adjuvant chemotherapy, was another limitation. But this was included in the multivariate analysis and subgroup analysis, and resulted in small shift to the overall outcomes.

In conclusion, the absolute number of preoperative peripheral blood monocyte count is an independent predictive factor that can stratify the survival of rectal cancer patients staged with pathological T3N0M0 after TME resection. Postoperative adjuvant treatment might be considered for this sort of patients with high-monocyte count.
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